Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide

Diagnostic Microbiology and Infectious Disease

Volumn 50, Issue 3, 2004, Pages 201-204

  Sader, Helio S ^a   Streit, Jennifer M ^a   Fritsche, Thomas R ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activity; Daptomycin; Gram positive cocci; Lipopeptide; Resistance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; DRUG ACTIVITY; DRUG POTENCY; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NORTH AMERICA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SOUTH AMERICA; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; WORLD HEALTH;

EID: 8444234261     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2004.07.002     Document Type: Article

References (19)

1. Arbeit E., Maki D., Tally F.P., Campanaro E., Eisenstein B.I. The Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 38:2004;1673-1681
2. Carpenter C.F., Chambers H.F. Daptomycin Another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis. 38:2004;994-1000
3. Dvorchik B.H., Brazier D., DeBruin M.F., Arbeit R.D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 47:2003;1318-1323
4. Fritsche T.R., Sader H.S., Jones R.N. Comparative activity and spectrum of broad spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci Report from the SENTRY Antimicrobial Surveillance Program (North America: 2001-2002). Diagn Microbiol Infect Dis. 47:2003;435-440
5. Fuchs P.C., Barry A.L., Brown S.D. Daptomycin susceptibility tests Interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis. 38:2000;51-58
6. Hershberger E., Donabedian S., Konstantinou K., Zervos M.J. Quinupristin-dalfopristin resistance in Gram-positive bacteria Mechanism of resistance and epidemiology. Clin Infect Dis. 38:2004;92-98
7. Jevitt L.A., Smith A.J., Williams P.P., Raney P.M., McGowan J.E. Jr, Tenover F.C. In vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist. 9:2003;389-393
8. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens A five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med. 24:2003;121-133
9. Laganas V., Alder J., Silverman J.A. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother. 47:2003;2682-2684
10. National Committee for Clinical Laboratory Standards (NCCLS) (2003). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Wayne, PA: NCCLS
11. National Committee for Clinical Laboratory Standards (NCCLS) (2004). Performance standards for antimicrobial susceptibility testing, 14th information supplement M100-S14. Wayne, PA: NCCLS
12. National Committee for Clinical Laboratory Standards (NCCLS) (2005). Performance standards for antimicrobial susceptibility testing, 15th information supplement M100-S15. Wayne, PA: NCCLS.
13. Package insert (2003). Cubicin (daptomycin for injection). Lexington MA. (Cubist Pharmaceuticals, Inc.) Available at http://www.cubist.com/shared/ cubicin_label.pdf. Accessed on September 22, 2003.
14. Sader H.S., Jones R.N., Ballow C.H., Biedenbach D.J., Cereda R.F. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America Results from the Global SMART (GSMART) Surveillance Study. Braz J Infect Dis. 5:2001;21-31
15. Sakoulas G., Eliopoulos G.M., Alder J., Thauvin-Eliopoulos C. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 47:2003;1714-1718
16. Silverman J.A., Perlmutter N.G., Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 47:2003;2538-2544
17. Streit J.M., Jones R.N., Sader H.S. Daptomycin activity and spectrum A worldwide sample of 6,737 Gram-positive organisms. J Antimicrob Chemother. 53:2004;669-674
18. Tally F.P., DeBruin M. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother. 46:2000;523-526
19. Thorne G.M., Alder J. Daptomycin A novel lipopeptide antibiotic. Clin Microbiol Newsletter. 24:2002;33-39